カテゴリ： 世界, 医療/バイオ, QYResearch

VLPベースワクチンの世界市場2023年：弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン

■ 英語タイトル：Global VLP-based Vaccine Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8508）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8508
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療機器
■ ページ数：96
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[VLPベースワクチンの世界市場2023年：弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

本調査資料はVLPベースワクチンのグローバル市場について調査・分析し、世界のVLPベースワクチン市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン）、用途別セグメント分析（肝炎、HPV、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Merck and Co.、GlaxoSmithKline、Pfizer、Dynavax Technologies、Sanofi、Wantai BioPharm、Serum Institute of India、Bharat Biotech、LG Chem、VBI Vaccinesなどが含まれています。VLPベースワクチンのグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、VLPベースワクチン市場規模を算出する際に考慮しました。

・VLPベースワクチン市場の概要
- 製品の定義
- VLPベースワクチンの種類別セグメント
- 世界のVLPベースワクチン市場規模：タイプ別分析（弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン）
- VLPベースワクチンの用途別セグメント
- 世界のVLPベースワクチン市場規模：用途別分析（肝炎、HPV、その他）
- 世界のVLPベースワクチン市場規模予測（2018年-2029年）
- VLPベースワクチンの平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- VLPベースワクチン市場の競争状況およびトレンド

・VLPベースワクチンの地域別市場規模
- 北米のVLPベースワクチン市場規模（2018年-2029年）
- 米国のVLPベースワクチン市場規模（2018年-2029年）
- ヨーロッパのVLPベースワクチン市場規模（2018年-2029年）
- アジア太平洋のVLPベースワクチン市場規模（2018年-2029年）
- 中国のVLPベースワクチン市場規模（2018年-2029年）
- 日本のVLPベースワクチン市場規模（2018年-2029年）
- 韓国のVLPベースワクチン市場規模（2018年-2029年）
- インドのVLPベースワクチン市場規模（2018年-2029年）
- オーストラリアのVLPベースワクチン市場規模（2018年-2029年）
- 中南米のVLPベースワクチン市場規模（2018年-2029年）
- 中東・アフリカのVLPベースワクチン市場規模（2018年-2029年）

・種類別セグメント：弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン
- 世界のVLPベースワクチンのタイプ別販売量（2018年-2023年）
- 世界のVLPベースワクチンのタイプ別売上（2018年-2023年）
- 世界のVLPベースワクチンのタイプ別価格

・用途別セグメント：肝炎、HPV、その他
- 世界のVLPベースワクチンの用途別販売量（2018年-2023年）
- 世界のVLPベースワクチンの用途別売上（2018年-2023年）
- 世界のVLPベースワクチンの用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Merck and Co.、GlaxoSmithKline、Pfizer、Dynavax Technologies、Sanofi、Wantai BioPharm、Serum Institute of India、Bharat Biotech、LG Chem、VBI Vaccines

・産業チェーンと販売チャネルの分析
- VLPベースワクチン産業チェーン分析
- VLPベースワクチンの主要原材料
- VLPベースワクチンの販売チャネル
- VLPベースワクチンのディストリビューター
- VLPベースワクチンの主要顧客

・VLPベースワクチン市場ダイナミクス
- VLPベースワクチンの業界動向
- VLPベースワクチン市場の成長ドライバ、課題、阻害要因

・調査の結論

・調査手法と情報源

Virus-like particles (VLPs) have evolved to become a widely accepted technology, especially in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new nanomaterials. In recent years, the technologies develop very fast that are used to characterize the structural integrity, stability, and components, including the encapsidated nucleic acids, of newly synthesized VLPs.
Highlights
The global VLP-based Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for VLP-based Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for VLP-based Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of VLP-based Vaccine include Merck and Co., GlaxoSmithKline, Pfizer, Dynavax Technologies, Sanofi, Wantai BioPharm, Serum Institute of India, Bharat Biotech and LG Chem, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for VLP-based Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding VLP-based Vaccine.
The VLP-based Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global VLP-based Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the VLP-based Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Merck and Co.
GlaxoSmithKline
Pfizer
Dynavax Technologies
Sanofi
Wantai BioPharm
Serum Institute of India
Bharat Biotech
LG Chem
VBI Vaccines
Segment by Type
Live-Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Toxoid Vaccines
Segment by Application
Hepatitis
HPV
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of VLP-based Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of VLP-based Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 VLP-based Vaccine Market Overview
1.1 Product Overview and Scope of VLP-based Vaccine
1.2 VLP-based Vaccine Segment by Type
1.2.1 Global VLP-based Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Live-Attenuated Vaccines
1.2.3 Inactivated Vaccines
1.2.4 Recombinant Vaccines
1.2.5 Toxoid Vaccines
1.3 VLP-based Vaccine Segment by Application
1.3.1 Global VLP-based Vaccine Market Value by Application: (2023-2029)
1.3.2 Hepatitis
1.3.3 HPV
1.3.4 Others
1.4 Global VLP-based Vaccine Market Size Estimates and Forecasts
1.4.1 Global VLP-based Vaccine Revenue 2018-2029
1.4.2 Global VLP-based Vaccine Sales 2018-2029
1.4.3 Global VLP-based Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 VLP-based Vaccine Market Competition by Manufacturers
2.1 Global VLP-based Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global VLP-based Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global VLP-based Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global VLP-based Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of VLP-based Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of VLP-based Vaccine, Product Type & Application
2.7 VLP-based Vaccine Market Competitive Situation and Trends
2.7.1 VLP-based Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest VLP-based Vaccine Players Market Share by Revenue
2.7.3 Global VLP-based Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 VLP-based Vaccine Retrospective Market Scenario by Region
3.1 Global VLP-based Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global VLP-based Vaccine Global VLP-based Vaccine Sales by Region: 2018-2029
3.2.1 Global VLP-based Vaccine Sales by Region: 2018-2023
3.2.2 Global VLP-based Vaccine Sales by Region: 2024-2029
3.3 Global VLP-based Vaccine Global VLP-based Vaccine Revenue by Region: 2018-2029
3.3.1 Global VLP-based Vaccine Revenue by Region: 2018-2023
3.3.2 Global VLP-based Vaccine Revenue by Region: 2024-2029
3.4 North America VLP-based Vaccine Market Facts & Figures by Country
3.4.1 North America VLP-based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America VLP-based Vaccine Sales by Country (2018-2029)
3.4.3 North America VLP-based Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe VLP-based Vaccine Market Facts & Figures by Country
3.5.1 Europe VLP-based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe VLP-based Vaccine Sales by Country (2018-2029)
3.5.3 Europe VLP-based Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific VLP-based Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific VLP-based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific VLP-based Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific VLP-based Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America VLP-based Vaccine Market Facts & Figures by Country
3.7.1 Latin America VLP-based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America VLP-based Vaccine Sales by Country (2018-2029)
3.7.3 Latin America VLP-based Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa VLP-based Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa VLP-based Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa VLP-based Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa VLP-based Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global VLP-based Vaccine Sales by Type (2018-2029)
4.1.1 Global VLP-based Vaccine Sales by Type (2018-2023)
4.1.2 Global VLP-based Vaccine Sales by Type (2024-2029)
4.1.3 Global VLP-based Vaccine Sales Market Share by Type (2018-2029)
4.2 Global VLP-based Vaccine Revenue by Type (2018-2029)
4.2.1 Global VLP-based Vaccine Revenue by Type (2018-2023)
4.2.2 Global VLP-based Vaccine Revenue by Type (2024-2029)
4.2.3 Global VLP-based Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global VLP-based Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global VLP-based Vaccine Sales by Application (2018-2029)
5.1.1 Global VLP-based Vaccine Sales by Application (2018-2023)
5.1.2 Global VLP-based Vaccine Sales by Application (2024-2029)
5.1.3 Global VLP-based Vaccine Sales Market Share by Application (2018-2029)
5.2 Global VLP-based Vaccine Revenue by Application (2018-2029)
5.2.1 Global VLP-based Vaccine Revenue by Application (2018-2023)
5.2.2 Global VLP-based Vaccine Revenue by Application (2024-2029)
5.2.3 Global VLP-based Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global VLP-based Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck and Co.
6.1.1 Merck and Co. Corporation Information
6.1.2 Merck and Co. Description and Business Overview
6.1.3 Merck and Co. VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck and Co. VLP-based Vaccine Product Portfolio
6.1.5 Merck and Co. Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Corporation Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GlaxoSmithKline VLP-based Vaccine Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Pfizer VLP-based Vaccine Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Dynavax Technologies
6.4.1 Dynavax Technologies Corporation Information
6.4.2 Dynavax Technologies Description and Business Overview
6.4.3 Dynavax Technologies VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Dynavax Technologies VLP-based Vaccine Product Portfolio
6.4.5 Dynavax Technologies Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sanofi VLP-based Vaccine Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Wantai BioPharm
6.6.1 Wantai BioPharm Corporation Information
6.6.2 Wantai BioPharm Description and Business Overview
6.6.3 Wantai BioPharm VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Wantai BioPharm VLP-based Vaccine Product Portfolio
6.6.5 Wantai BioPharm Recent Developments/Updates
6.7 Serum Institute of India
6.6.1 Serum Institute of India Corporation Information
6.6.2 Serum Institute of India Description and Business Overview
6.6.3 Serum Institute of India VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Serum Institute of India VLP-based Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
6.8 Bharat Biotech
6.8.1 Bharat Biotech Corporation Information
6.8.2 Bharat Biotech Description and Business Overview
6.8.3 Bharat Biotech VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bharat Biotech VLP-based Vaccine Product Portfolio
6.8.5 Bharat Biotech Recent Developments/Updates
6.9 LG Chem
6.9.1 LG Chem Corporation Information
6.9.2 LG Chem Description and Business Overview
6.9.3 LG Chem VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 LG Chem VLP-based Vaccine Product Portfolio
6.9.5 LG Chem Recent Developments/Updates
6.10 VBI Vaccines
6.10.1 VBI Vaccines Corporation Information
6.10.2 VBI Vaccines Description and Business Overview
6.10.3 VBI Vaccines VLP-based Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 VBI Vaccines VLP-based Vaccine Product Portfolio
6.10.5 VBI Vaccines Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 VLP-based Vaccine Industry Chain Analysis
7.2 VLP-based Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 VLP-based Vaccine Production Mode & Process
7.4 VLP-based Vaccine Sales and Marketing
7.4.1 VLP-based Vaccine Sales Channels
7.4.2 VLP-based Vaccine Distributors
7.5 VLP-based Vaccine Customers
8 VLP-based Vaccine Market Dynamics
8.1 VLP-based Vaccine Industry Trends
8.2 VLP-based Vaccine Market Drivers
8.3 VLP-based Vaccine Market Challenges
8.4 VLP-based Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global VLP-based Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global VLP-based Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global VLP-based Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global VLP-based Vaccine Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global VLP-based Vaccine Sales Market Share by Manufacturers (2018-2023)
Table 6. Global VLP-based Vaccine Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global VLP-based Vaccine Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market VLP-based Vaccine Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of VLP-based Vaccine, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of VLP-based Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of VLP-based Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of VLP-based Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global VLP-based Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VLP-based Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global VLP-based Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global VLP-based Vaccine Sales by Region (2018-2023) & (K Units)
Table 18. Global VLP-based Vaccine Sales Market Share by Region (2018-2023)
Table 19. Global VLP-based Vaccine Sales by Region (2024-2029) & (K Units)
Table 20. Global VLP-based Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global VLP-based Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global VLP-based Vaccine Revenue Market Share by Region (2018-2023)
Table 23. Global VLP-based Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global VLP-based Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America VLP-based Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America VLP-based Vaccine Sales by Country (2018-2023) & (K Units)
Table 27. North America VLP-based Vaccine Sales by Country (2024-2029) & (K Units)
Table 28. North America VLP-based Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America VLP-based Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe VLP-based Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe VLP-based Vaccine Sales by Country (2018-2023) & (K Units)
Table 32. Europe VLP-based Vaccine Sales by Country (2024-2029) & (K Units)
Table 33. Europe VLP-based Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe VLP-based Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific VLP-based Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific VLP-based Vaccine Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific VLP-based Vaccine Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific VLP-based Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific VLP-based Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America VLP-based Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America VLP-based Vaccine Sales by Country (2018-2023) & (K Units)
Table 42. Latin America VLP-based Vaccine Sales by Country (2024-2029) & (K Units)
Table 43. Latin America VLP-based Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America VLP-based Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa VLP-based Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa VLP-based Vaccine Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa VLP-based Vaccine Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa VLP-based Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa VLP-based Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global VLP-based Vaccine Sales (K Units) by Type (2018-2023)
Table 51. Global VLP-based Vaccine Sales (K Units) by Type (2024-2029)
Table 52. Global VLP-based Vaccine Sales Market Share by Type (2018-2023)
Table 53. Global VLP-based Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global VLP-based Vaccine Revenue (US$ Million) by Type (2018-2023)
Table 55. Global VLP-based Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global VLP-based Vaccine Revenue Market Share by Type (2018-2023)
Table 57. Global VLP-based Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global VLP-based Vaccine Price (US$/Unit) by Type (2018-2023)
Table 59. Global VLP-based Vaccine Price (US$/Unit) by Type (2024-2029)
Table 60. Global VLP-based Vaccine Sales (K Units) by Application (2018-2023)
Table 61. Global VLP-based Vaccine Sales (K Units) by Application (2024-2029)
Table 62. Global VLP-based Vaccine Sales Market Share by Application (2018-2023)
Table 63. Global VLP-based Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global VLP-based Vaccine Revenue (US$ Million) by Application (2018-2023)
Table 65. Global VLP-based Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global VLP-based Vaccine Revenue Market Share by Application (2018-2023)
Table 67. Global VLP-based Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global VLP-based Vaccine Price (US$/Unit) by Application (2018-2023)
Table 69. Global VLP-based Vaccine Price (US$/Unit) by Application (2024-2029)
Table 70. Merck and Co. Corporation Information
Table 71. Merck and Co. Description and Business Overview
Table 72. Merck and Co. VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Merck and Co. VLP-based Vaccine Product
Table 74. Merck and Co. Recent Developments/Updates
Table 75. GlaxoSmithKline Corporation Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. GlaxoSmithKline VLP-based Vaccine Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Pfizer VLP-based Vaccine Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Dynavax Technologies Corporation Information
Table 86. Dynavax Technologies Description and Business Overview
Table 87. Dynavax Technologies VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Dynavax Technologies VLP-based Vaccine Product
Table 89. Dynavax Technologies Recent Developments/Updates
Table 90. Sanofi Corporation Information
Table 91. Sanofi Description and Business Overview
Table 92. Sanofi VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Sanofi VLP-based Vaccine Product
Table 94. Sanofi Recent Developments/Updates
Table 95. Wantai BioPharm Corporation Information
Table 96. Wantai BioPharm Description and Business Overview
Table 97. Wantai BioPharm VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Wantai BioPharm VLP-based Vaccine Product
Table 99. Wantai BioPharm Recent Developments/Updates
Table 100. Serum Institute of India Corporation Information
Table 101. Serum Institute of India Description and Business Overview
Table 102. Serum Institute of India VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Serum Institute of India VLP-based Vaccine Product
Table 104. Serum Institute of India Recent Developments/Updates
Table 105. Bharat Biotech Corporation Information
Table 106. Bharat Biotech Description and Business Overview
Table 107. Bharat Biotech VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Bharat Biotech VLP-based Vaccine Product
Table 109. Bharat Biotech Recent Developments/Updates
Table 110. LG Chem Corporation Information
Table 111. LG Chem Description and Business Overview
Table 112. LG Chem VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. LG Chem VLP-based Vaccine Product
Table 114. LG Chem Recent Developments/Updates
Table 115. VBI Vaccines Corporation Information
Table 116. VBI Vaccines Description and Business Overview
Table 117. VBI Vaccines VLP-based Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. VBI Vaccines VLP-based Vaccine Product
Table 119. VBI Vaccines Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. VLP-based Vaccine Distributors List
Table 123. VLP-based Vaccine Customers List
Table 124. VLP-based Vaccine Market Trends
Table 125. VLP-based Vaccine Market Drivers
Table 126. VLP-based Vaccine Market Challenges
Table 127. VLP-based Vaccine Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of VLP-based Vaccine
Figure 2. Global VLP-based Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global VLP-based Vaccine Market Share by Type in 2022 & 2029
Figure 4. Live-Attenuated Vaccines Product Picture
Figure 5. Inactivated Vaccines Product Picture
Figure 6. Recombinant Vaccines Product Picture
Figure 7. Toxoid Vaccines Product Picture
Figure 8. Global VLP-based Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global VLP-based Vaccine Market Share by Application in 2022 & 2029
Figure 10. Hepatitis
Figure 11. HPV
Figure 12. Others
Figure 13. Global VLP-based Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global VLP-based Vaccine Market Size (2018-2029) & (US$ Million)
Figure 15. Global VLP-based Vaccine Sales (2018-2029) & (K Units)
Figure 16. Global VLP-based Vaccine Average Price (US$/Unit) & (2018-2029)
Figure 17. VLP-based Vaccine Report Years Considered
Figure 18. VLP-based Vaccine Sales Share by Manufacturers in 2022
Figure 19. Global VLP-based Vaccine Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest VLP-based Vaccine Players: Market Share by Revenue in 2022
Figure 21. VLP-based Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 22. Global VLP-based Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 23. North America VLP-based Vaccine Sales Market Share by Country (2018-2029)
Figure 24. North America VLP-based Vaccine Revenue Market Share by Country (2018-2029)
Figure 25. United States VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Canada VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 27. Europe VLP-based Vaccine Sales Market Share by Country (2018-2029)
Figure 28. Europe VLP-based Vaccine Revenue Market Share by Country (2018-2029)
Figure 29. Germany VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. France VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. U.K. VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Italy VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Russia VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Asia Pacific VLP-based Vaccine Sales Market Share by Region (2018-2029)
Figure 35. Asia Pacific VLP-based Vaccine Revenue Market Share by Region (2018-2029)
Figure 36. China VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Japan VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. South Korea VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. India VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. Australia VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. China Taiwan VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Indonesia VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Thailand VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Malaysia VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Latin America VLP-based Vaccine Sales Market Share by Country (2018-2029)
Figure 46. Latin America VLP-based Vaccine Revenue Market Share by Country (2018-2029)
Figure 47. Mexico VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Brazil VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Argentina VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Middle East & Africa VLP-based Vaccine Sales Market Share by Country (2018-2029)
Figure 51. Middle East & Africa VLP-based Vaccine Revenue Market Share by Country (2018-2029)
Figure 52. Turkey VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Saudi Arabia VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. UAE VLP-based Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Global Sales Market Share of VLP-based Vaccine by Type (2018-2029)
Figure 56. Global Revenue Market Share of VLP-based Vaccine by Type (2018-2029)
Figure 57. Global VLP-based Vaccine Price (US$/Unit) by Type (2018-2029)
Figure 58. Global Sales Market Share of VLP-based Vaccine by Application (2018-2029)
Figure 59. Global Revenue Market Share of VLP-based Vaccine by Application (2018-2029)
Figure 60. Global VLP-based Vaccine Price (US$/Unit) by Application (2018-2029)
Figure 61. VLP-based Vaccine Value Chain
Figure 62. VLP-based Vaccine Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • ブリスターフリーシリンジワクチンのグローバル市場展望 2023年-2029年：弱毒化生ワクチン、不活化ワクチン、mRNAワクチン、DNA組換えワクチン、その他
  • 結核病ワクチンの世界市場2023年：予防ワクチン、曝露後ワクチン、その他
  • 細胞培養系インフルエンザワクチンのグローバル市場展望 2023年-2029年：バイアル、充填済み
  • 結合型ワクチンのグローバル市場（2022年-2029年）：一価結合型ワクチン、多価結合型ワクチン
  • 世界の新型コロナウイルス感染症予防用VPM1002（結核BCGワクチン）市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8508 )"VLPベースワクチンの世界市場2023年：弱毒生ワクチン、不活化ワクチン、組換えワクチン、トキソイドワクチン" (英文：Global VLP-based Vaccine Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。